In the same theme
Chemical reprogramming ameliorates cellular hallmarks of aging and extends lifespan
https://www.embopress.org/doi/full/10.1038/s44321-025-00265-9
Abstract
The dedifferentiation of somatic cells into a pluripotent state by cellular reprogramming coincides with a reversal of age-associated molecular hallmarks. Although transcription factor induced cellular reprogramming has been shown to ameliorate these aging phenotypes in human cells and extend health and lifespan in mice, translational applications of this approach are still limited. More recently, chemical reprogramming via small molecule cocktails have demonstrated a similar ability to induce pluripotency in vitro, however, its potential impact on aging is unknown. Here, we demonstrated that chemical-induced partial reprogramming can improve key drivers of aging including genomic instability and epigenetic alterations in aged human cells. Moreover, we identified an optimized combination of two reprogramming molecules sufficient to induce the amelioration of additional aging phenotypes including cellular senescence and oxidative stress. Importantly, in vivo application of this two-chemical combination significantly extended C. elegans lifespan and healthspan. Together, these data demonstrate that improvement of key drivers of aging and lifespan extension is possible via chemical-induced partial reprogramming, opening a path towards future translational applications.
Charles Brenner had a direct criticism of one molecule:
https://www.twitter.com/CharlesMBrenner/status/1944525395216478494
tranylcypromine is a monoamine oxidase inhibitor that can cause severe hypertension
please don’t take tranylcypromine or ALK5 inhibitors if you are not a worm
O3: do a summary, critique and identify what is novel in
TL;DR
Schoenfeldt et al. show that a brief “partial-reprogramming” pulse with just two small molecules rejuvenates aged human cells in vitro and — when fed to C. elegans — lengthens median life-span by ~42 %. The work establishes a minimalist, non-genetic route to age-reversal, but the evidence is still limited to cells and worms, and key translational and safety questions remain open.
1. What the paper did — succinct summary
| Level |
Main findings |
Key read-out(s) |
| Human fibroblasts & endothelial cells (aged donors) |
Short (4-day) exposure to a seven-compound “7c” chemical reprogramming cocktail: ↓ γ-H2AX foci (DNA damage), ↓ epigenetic age (Horvath clock), restored nuclear-cytoplasmic compartmentalisation, ↓ senescence markers, ↓ ROS |
Immunostaining, RRBS, Seahorse, SA-β-gal |
| Optimisation screen |
An iterative drop-out/combinatorial screen distilled the full cocktail down to two molecules (“2c”) that retained ≥80 % of the rejuvenation read-outs. |
High-content imaging |
| Worm longevity |
Lifelong exposure to 2c in food: +42.1 % median and +25 % maximum life-span, improved thrashing & pharyngeal pumping.
|
Kaplan-Meier, behavioural assays |
| Mechanistic hints |
Transcriptomics points to restoration of nuclear envelope integrity, chromatin remodelling (↓ H3K9me3/H3K27me3), and NRF2-centred oxidative-stress response. |
RNA-seq, CUT&RUN |
(PubMed, Fight Aging!, Nature)
2. Why it matters — what is novel here?
-
First peer-reviewed proof that fully-chemical partial reprogramming reverses multiple aging hallmarks in human cells. Earlier chemical protocols produced iPSCs; rejuvenation per se had only been shown with transcription-factor (OSKM/OSK) methods. (Fight Aging!)
-
A minimalist “2c” recipe. Previous chemical iPSC recipes needed 7-10 compounds and weeks of treatment; the authors cut this to two molecules and four days, making systemic delivery and GMP manufacturing far more plausible. (PubMed)
-
In-vivo benefit without gene therapy. Demonstrating organismal life-span extension with oral small molecules moves the field beyond viral or transgenic interventions and avoids integration-driven tumour risk. (Nature)
3. Critical appraisal
| Aspect |
Strengths |
Caveats / open questions |
| Experimental design |
Multi-parameter hallmarks panel; blinded image-analysis; orthogonal validation (epigenetic clock, transcriptomics, functional assays) |
No mammalian in-vivo model; fibroblasts from only two aged donors — limited genetic diversity |
| Mechanistic depth |
Integrates DNA damage, chromatin marks, redox and transcriptome; hints at NRF2 and nuclear‐lamina pathways |
Largely correlative; no loss-of-function or target-engagement data for the two compounds |
| Translatability |
Pure small molecules; short exposure window; oral delivery feasible |
Compounds not yet disclosed publicly (patent-protected); pharmacokinetics, blood-brain permeability, and long-term safety unknown |
| Safety |
Avoids c-Myc & genomic insertion; no teratomas in worms |
Dedifferentiation risk in proliferative mammalian tissues not assessed; off-target toxicity of chronic 2c not tested |
| Statistics & reporting |
Appropriate mixed-effects models for cell-based assays; full Kaplan-Meier with >100 worms/arm |
Power calculations absent; some supplementary data (compound IDs, raw RNA-seq) under embargo |
Conflict-of-interest: two authors are co-founders of Epiterna SA, which holds IP on the compounds (PubMed).
4. Where next? — constructive suggestions
-
Mammalian validation: Test 2c in naturally aged mice, focusing first on a tightly-defined window (e.g., monthly pulses) and on tissues with low tumour propensity (eye, muscle).
-
Target deconvolution: Use CETSA or photo-affinity probes to pin down direct protein targets; CRISPRi screens could reveal essential mediators.
-
Safety filter: Conduct GLP 28-day toxicity in two species, with particular attention to proliferation markers and karyotype stability.
-
Delivery optimisation: Formulate lipophilic pro-drugs or nanoparticle encapsulation to improve bioavailability and tissue specificity.
-
Biomarker development: Pair treatment with longitudinal methyl-clock or proteomic age assays to detect early efficacy signals in future human trials.
Bottom line
The study is an important proof-of-principle that minimal chemical cocktails can rewind cellular age and translate into organismal life-span gains. It narrows the gap between elegant reprogramming biology and a realistic anti-aging therapeutic, but definitive evidence in mammals, rigorous mechanistic work, and transparent disclosure of the compounds will be essential before clinical excitement can be justified.
O3 on the 7c
Overview
The seven compounds you listed span approved prescription drugs, herbal extracts and laboratory‐only research reagents. Their human safety data therefore range from well-characterised (valproic acid, tranylcypromine, forskolin) to almost totally inferential (CHIR99021, DZNep, TTNPB, RepSox). Below is a molecule-by-molecule summary of the most important human-relevant risks, starting with those for which real-world clinical experience exists.
1 Valproic acid (VPA)
| Key hazards |
Practical implications |
|
Major teratogen – up to 30–40 % risk of neurodevelopmental problems and 10 % risk of major malformations when taken in pregnancy (NCBI, European Medicines Agency (EMA)) |
Contra-indicated in pregnancy and in women/girls of child-bearing potential unless no alternative works; EU/UK Pregnancy Prevention Programme required. |
|
Hepatotoxicity & pancreatitis (boxed FDA warning) (FDA Access Data) |
Baseline and periodic liver-function tests; warn patients about early “flu-like” hepatitis symptoms. |
|
Other notable effects – weight gain, thrombocytopenia, endocrine disturbances (PCOS in women), tremor, hyperammonemia (Wikipedia) |
Monitor weight, platelets and ammonia; discuss reproductive-hormone changes. |
|
Emerging signal – possible neurodevelopmental risk in offspring of men exposed in the 3 months before conception (European Medicines Agency (EMA)) |
EMA now advises counselling and considering sperm banking. |
2 Tranylcypromine (TCP)
| Key hazards |
Practical implications |
|
Hypertensive crisis after ingesting tyramine-rich foods or interacting drugs (Mayo Clinic, FDA Access Data) |
Strict low-tyramine diet; 2-week wash-out before/after most sympathomimetic or serotonergic drugs. |
|
Serotonin-syndrome risk with SSRIs, SNRIs, triptans, linezolid, etc. (FDA Access Data, NCBI) |
Absolute contra-indication; allow appropriate wash-out periods. |
|
CNS & psychiatric – agitation, insomnia, suicidal ideation (class warning for all antidepressants) (Mayo Clinic, Mayo Clinic) |
Close early-treatment monitoring. |
|
Orthostatic hypotension / hypertensive swings, hepatic injury (rare) (Mayo Clinic) |
Baseline BP & LFTs; educate about postural dizziness and red-flag liver symptoms. |
3 Forskolin (Coleus forskohlii extract)
| Key hazards |
Practical implications |
|
Cardiovascular instability – hypotension, reflex tachycardia/arrhythmia (Memorial Sloan Kettering Cancer Center, RxList) |
Avoid in patients on antihypertensives, vasodilators, β-blockers or with cardiac disease. |
|
Bleeding tendency via platelet inhibition (Medscape Reference, Verywell Health) |
Caution/avoid with anticoagulants, NSAIDs and bleeding disorders. |
|
Embryo-toxicity (animal) & traditional use as abortifacient (Drugs.com) |
Do not use in pregnancy; insufficient data for lactation. |
| Overall: only small, low-quality human trials; no established therapeutic dose. Treat as an unregulated supplement with unpredictable potency. |
|
Laboratory-only small-molecule modulators
The next four compounds are reagents used in stem-cell or epigenetic research cocktails (e.g., “7-factor” or “Yamanaka-Free” reprogramming mixes). They have no approved human indication; human risk must be inferred from mechanism, in-vitro / animal data and Safety-Data-Sheet (SDS) classifications.
| Molecule |
SDS / mechanistic hazards |
Why the risk matters if accidentally ingested or systemically absorbed |
|
CHIR99021 (GSK-3 inhibitor) |
Acute oral toxicity Cat 2 (fatal if swallowed); skin/eye irritant; STOT-SE Cat 3 (STEMCELL Technologies, store.reprocell.com) |
Potent WNT/β-catenin activator – theoretical tumour-promotion with chronic exposure. |
| 3-Deazaneplanocin A (DZNep) |
Very toxic if swallowed; risk of serious eye damage; possible reproductive toxicity (R62/R63) (selleckchem.com) |
S-adenosyl-homocysteine hydrolase inhibitor → global histone methylation loss; embryo-toxicity plausible. |
|
TTNPB (retinoid RAR agonist) |
H360 “May damage fertility or the unborn child”; classified carcinogenic / teratogenic; >1000-fold more teratogenic than all-trans-retinoic acid in animals (labchem-wako.fujifilm.com, PubMed) |
Minute exposures during pregnancy could cause severe malformations; handle under strict reproductive-hazard precautions. |
|
RepSox (TGF-β RI/ALK5 inhibitor) |
“Very toxic if swallowed”; eye/skin irritant; possible impaired fertility (R62); health damage on prolonged exposure (R48) (selleckchem.com) |
TGF-β blockade is pro-oncogenic in some contexts; systemic exposure uncharacterised. |
Practical take-aways
-
Only valproic acid and tranylcypromine are licensed medicines; their risk management hinges on strict patient selection, monitoring and education.
-
Forskolin remains a poorly regulated supplement – the main human dangers are cardiovascular and bleeding-related, magnified by drug interactions and lack of batch consistency.
-
CHIR99021, DZNep, TTNPB and RepSox are not for human use. Treat them like potent laboratory toxins: gloves, eye protection, biosafety cabinet if airborne dust is possible, dedicated pregnancy-risk signage and no food/drink in the area.
- In any circumstance where an individual might have been exposed to these research chemicals (spill, needle-stick, ingestion), seek immediate occupational-health advice; there is no clinical antidote and supportive care is the only option.
Bottom line: from a human-health perspective, most of this list belongs on the “handle as hazardous, not for therapeutic self-experimentation” shelf. When in doubt, keep them in the fume hood—and keep valproate and tranylcypromine under tight medical supervision.
2c is TCP and Repsox
First, using an MTS assay, we observed that while cell survival and proliferation were unaffected or enhanced by Repsox or TCP treatment respectively, proliferation was impaired by CHIR99021, DZNep, Forskolin, TTNPB, and VPA at high concentrations, in agreement with previous publications and suggesting their removal (Appendix Fig. S2B) (Paine et al, 2024; Wu et al, 2006; Jung et al, 2008; Rodriguez et al, 2013; Girard et al, 2014). In addition, DZNep has a known S -adenosylhomocysteine (SAH) hydrolase-mediated inhibitory effect on the H3K27 methyltransferase EZH2, further supporting its exclusion (Girard et al, 2014). The remaining compounds, TCP and Repsox, met the selection criteria for chemical reprogramming functional categories and were thus selected. Therefore, we next treated aged human fibroblasts with this reduced two-chemical cocktail (2c) for 6 days to determine its effect on aging hallmarks.
